Bristol Myers Squibb, UbiVac to assess combination immunotherapy for advanced triple-negative breast cancer

Bristol Myers Squibb, UbiVac to assess combination immunotherapy for advanced triple-negative breast cancer

Submitted by admin on June 10, 2020 - 10:54am
Source: 
Pharmaceutical Business Review
News Tags: 
UbiVac
Bristol-Myers Squibb
clinical trials
triple negative breast cancer
DPV-001
Headline: 
Bristol Myers Squibb, UbiVac to assess combination immunotherapy for advanced triple-negative breast cancer
snippet: 

UbiVac has announced clinical trial collaboration Bristol Myers Squibb (BMS) on the combination immunotherapy for advanced triple negative breast cancer.

Do Not Allow Advertisers to Use My Personal information